APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Apnimed, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026

$16.59−1.17 (-6.56%)

Close on Oct 19, 2026

Market cap: $536.90M
P/E (TTM): –
Dividend yield: –

Apnimed, Inc. income statement

Annual data is not available for this company.

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	12	–	17	–
Research & Development	9.90	–	16	–
General & Administrative	13	–	5.35	–
Operating Expenses	24	–	23	–
Operating Income	-12	–	-5.94	–
Income from Equity Investments	0.20	–	64	–
Other Non-Operating Income	138	–	0.31	–
Pretax Income	126	–	-5.63	–
Income Tax Expense	0	–	0	–
Income from Continuing Operations	126	–	-5.63	–
Income from Discontinued Operations	-0.18	–	-64	–
Net Income	126	68	-69	-29
Net Income to Common	126	–	–	–
EPS (Basic)(per share)	26.25	–	-14.61	–
EPS (Diluted)(per share)	3.89	–	-14.61	–
Shares Outstanding (Basic, Weighted)(shares)	4.80	–	4.75	–
Shares Outstanding (Diluted, Weighted)(shares)	32	–	4.75	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 5.19
Debt to equity: -0.23
Debt to assets: 20.6%
Cash to current liabilities: 485.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –